Daily analysis of Indian market events grounded in real corporate filings. Every claim is backed by what companies actually said in their annual reports and quarterly results.
A US Senate bill could impose 100% tariffs on India's Russian crude imports. We dig into filings from CHENNPETRO, MRPL, BPCL, HPCL, Reliance, and Great Eastern Shipping to map who gets hurt and who quietly benefits.
The US Senate's Russia sanctions bill threatens India's 48% Russian crude lifeline. While refiners face margin compression, domestic oil producers and renewable energy companies stand to gain.
The US Senate passed a bill threatening India with 100% tariffs over Russian oil. India's pharma giants — which supply over 40% of US generic drugs — have the most revenue at stake.
A US court just struck down the universal 10% tariff on Indian goods. But 5 NSE-listed exporters had already restructured their businesses to survive — and now stand to gain the most from tariff relief.
The India-UK FTA eliminates 8-12% tariffs on 99% of Indian exports. We dug into filings to find which textile and auto component makers have the most UK exposure and the strongest positioning to benefit.
India's triple trade deal tailwind — UK FTA, EU agreement, and US tariff reset — creates a multi-year catalyst for textile exporters. Five NSE-listed companies with the strongest filing evidence.
Brent crude plunged below $80 after Trump halted the Iran attack. We dug through filings to find which Indian companies benefit the most — from IndiGo's fuel bill to Apollo Tyres' synthetic rubber costs.
China's US textile exports dropped from $28 billion to $19 billion in one year. With new FTAs with the UK and EU, Indian apparel and home textile companies are capturing that lost share. Here are the stocks best positioned.
The UK-India trade deal is going live with zero import duties on textiles. We dig into filings from Gokaldas, Welspun, S.P. Apparels, Pearl Global, and Fineotex to find who has been quietly preparing.
The US Senate Russia sanctions bill threatens 100% tariffs on India over Russian oil imports. We dig into refiner filings to find who is most exposed, who has diversified, and which company is the unexpected winner.
While headlines scream pain for Indian exporters, companies like Hindalco, Gokaldas, and India's pharma giants have built-in defenses — and some stand to actually benefit.
Trump proposes up to 200% tariffs on generic drugs. India supplies 45% of US generics. We ranked the five largest Indian pharma exporters by US revenue exposure using their own filings.
Oil prices hit a six-week high near $96 as US-Iran tensions escalate. IndiGo just posted a Q1 FY27 loss. We map which stocks bleed and which ones win using corporate filing data.
Companies with US manufacturing plants are positioned to weather Trump's generic drug tariff, while pure exporters face margin risk. A filing-backed look at who's prepared.
Trump announced tariffs up to 200% on generic drug imports. We dug into filings of the six most exposed Indian pharma companies — two are already manufacturing in the US.